AI Earnings Keep Confirming The Buildout
Our Trade Performance, Updated
Before we get into today’s trade alert, here’s a look at our trade performance year-to-date.
You can see all of our completed trades in this spreadsheet.
The Evidence Keeps Building
During the momentum correction, we wrote several posts arguing that the selloff in AI infrastructure stocks was obscuring what the companies themselves were saying: demand was still accelerating through increasingly specialized parts of the stack.
This week’s reports have continued to support that thesis. Nebius Group N.V. (NBIS 0.00%↑), on which we have an open trade, reported second-quarter revenue of $582 million, up 454% year over year; annualized run-rate revenue of $3 billion; and four new large AI-cloud contracts averaging more than $1 billion each. Its shares jumped 34% on Wednesday.
The operating evidence shows the buildout expanding. Share-price reactions still depend on the expectations already embedded in each stock, which makes entry price decisive.
Today’s two AI trades approach that evidence differently. The first is a longer-dated trade on a semiconductor-equipment company we traded successfully earlier this year. The second is a short-dated earnings trade on another equipment name. Both stocks appeared in our system’s Top Names on Wednesday night.
One More QURE Trade
Our third trade is a different kind of asymmetric setup. In June, we wrote about the FDA reopening an accelerated-approval path for uniQure N.V. (QURE 0.00%↑) and its AMT-130 gene therapy for Huntington’s disease.
We already have shorter-dated QURE exposure, but our Multibaggers analysts remain excited by the stock’s potential. As a reminder, Multibaggers are a subset of accounts from our Market Watchers X list with documented, 100%+ winners. Today’s final QURE structure has a January 2028 expiration designed to span the catalyst window we expect to matter most: remaining clinical updates, the planned U.S. and U.K. regulatory path, and early European engagement. Then we’ll let our QURE structures work without adding more exposure.
Today’s First Top Names Trade
Semiconductor manufacturing equipment / AI-capex theme
RSI: 53; Chartmill Technical Rating: 8; Setup Rating: 6; Fundamental Rating: 7.
We're saving our AI stack trades for Portfolio Armor Substack subscribers, who can read about them here, but you can read about our QURE trade below. First, if you want to become a Subscriber to our Substack, you can do so via this widget:
Today’s Multibaggers Trade
Huntington’s gene therapy / full regulatory-window theme
RSI: 61; Chartmill Technical Rating: 10; Setup Rating: 3; Fundamental Rating: 3.
This trade hasn’t filled yet.
The low Setup rating reflects QURE’s volatility and proximity to its recent highs. This is a deliberate catalyst-driven exception: the January 2028 expiration is designed to cover the remaining AMT-130 clinical and regulatory runway. Every leg shares that expiration, so the structure can remain in place across the catalyst window.
The complete structure was worth a $3.32 credit under Black-Scholes, $3.36 under Bjerksund-Stensland, and $3.48 under a Cox-Ross-Rubinstein binomial model. At our minimum net credit of $3.50, the max gain on 1 contract is $2,350, and the max loss is $650.
At expiration, the trade keeps its $350 opening credit if QURE finishes between $45 and $65, with a downside breakeven of $41.50. The maximum gain occurs at or above $85.
Unless otherwise indicated, all trades are day orders and will be canceled at the end of the day if they don’t fill.
Exiting This Trade
If this QURE trades fill, my plan:
